Welcome, visitor! [ Login

Mr. Robert Friedland Joins Board of Directors

News

Dragon Pharmaceuticals Inc. is very pleased to announce the appointment of international financier Robert Friedland to the Board of Directors, effective immediately.

Friedland is chairman and president of Ivanhoe Capital Corporation, a Singapore-based venture capital company with worldwide interests in resource and high-tech companies.

Companies developed or financed by Friedland and Ivanhoe Capital include Ivanhoe Energy, Ivanhoe Mines, Diamond Fields Resources, Golden Star Resources, Fairbanks Gold, Cyber City Holdings (a Chinese company establishing high-tech science parks) and SINA.com (a global Internet media company).

Friedland is chairman and acting president of Ivanhoe Mines and deputy chairman of Ivanhoe Energy, which is active in China in partnership with China National Petroleum Corporation through its subsidiary Sunwing Energy Ltd. Friedland was named Developer of the Year in 1996 by the Canadian Prospectors and Developers Association of Canada for his work in establishing and financing international mining and exploration companies, including Diamond Fields, owner and developer of the Voisey’s Bay nickel deposit, which was sold to INCO Limited for CDN $4.3 billion.

The Company is very pleased with the appointment of Friedland. Dragon has entered into an exciting time of growth and development. Friedland brings a wealth of experience to the Company and will undoubtedly be an invaluable addition to the Board of Directors. The entire Board of Directors looks forward to working with Friedland during the years ahead.

The Company also wishes to announce that Jackson Cheng has resigned as a director of the Company to allow for the appointment of Friedland. The Board wishes to thank Cheng for his contributions to the management of the Company.

Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production and marketing of biodrugs throughout China.

3690 total views, 1 today

$10 Million Private Placement Closed

News

The Company is pleased to announce the completion of its recent private placement of 4,258,000 units (the “Units”) at a price of $2.50 per unit for gross proceeds of $10,645,000. Each Unit consists of one common share and one non-transferable share purchase warrant (the “Warrant”). Each Warrant entitles the holder to purchase one common share at a price of $2.50 for a period of one year.

One of the significant placees is the Chow Tai Fook Group, the parent company of the New World Development Company Limited, one of the largest business conglomerates in Hong Kong. New World is a significant player in real estate, infrastructure projects, strategic investments, hotel management, telecommunications, and public transportation. Mr. Cheng Yu-Tung, the Chairman of the Chow Tai Fook Group also serves as Chairman of New World, which is one of the largest shareholders in China.com. Mr. Cheng also serves as a Director of several large Hong Kong companies including Hang Seng Bank Limited.

Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production, and marketing of biodrugs throughout China.

The foregoing includes forward looking statements and readers should not place undue reliance on such forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.

1869 total views, 1 today

EPO Commercial Production Achieved

News

Dragon Pharmaceuticals Inc. is very pleased to announce that a new vector technology has been successfully applied to its EPO production plant at Nanjing Huaxin, China. The yield of the improved EPO cell line has reached 45 mg per liter, well above the Company’s initial expectation.

Optimal annual EPO production from each of the bioreactors is estimated to be over one million doses. With this major technological breakthrough, Huaxin’s annual EPO production capacity can be increased up to five million doses and the direct production cost is being reduced dramatically.

EPO sales in China have increased substantially since the expansion of Huaxin’s marketing network in China. Several high-profile marketing executives were added to Huaxin’s sales team as previously announced.

Huaxin sold approximately 27,000 doses of EPO in China in November. Dragon is working toward establishing a strong marketing team to distribute its EPO produced at Huaxin plant into the international markets. A business to business web site for the marketing of EPO on the internet is currently being investigated to potentially sell Dragon’s EPO to the international market.

The management of the Company is very encouraged by the above major corporate development, which proves the technological platform developed by the Company in China. The Company has achieved the objectives of the first phase of its business plan in a short period of time.

Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production, and marketing of biodrugs throughout China.

2428 total views, 1 today

New Directors Appointed

News

The Company is pleased to announce that Mr. Philip Yuen Pak Yiu and Dr. Yiu Kwong Sun have been appointed to the Board of Directors.

Mr. Yuen has been a legal practitioner in Hong Kong since graduating from law school in London, England in 1961. In 1965, he established the law firm Yung, Yu, Yuen and Co. and is now the principal partner of the firm. Mr. Yuen has over 30 years experience in the legal field and has been a director of several large listed companies in various sectors. He is a director of the Association of China-appointed Attesting Officers Limited in Hong Kong, a standing committee member of the Chinese General Chamber of Commerce of Hong Kong, a member of the National Committee of the Chinese People Political Consultative Conference and an arbitrator of the China International Economic and Trade Arbitration Commission.

Dr. Sun graduated from the University of Hong Kong Faculty of Medicine in 1967. He is a Founding Fellow of the Hong Kong College of Family Physicians and a Fellow of the Hong Kong Academy of Medicine. He is the Chairman of the Dr. Sun Medical Centre Limited which has been operating a network of medical centres in Hong Kong and China for the past 20 years. He is also the Administration Partner of United Medical Practice, which manages a large network of medical facilities throughout Hong Kong and Macau. Dr. Sun has been a member of the Dr. Cheng Yu Fellowship Committee of Management of the University of Hong Kong Faculty of Medicine since 1997.

The Company also wishes to announce that Mr. Shaun Maskerine has resigned as a Director of the Company to allow for the appointment of new directors. The Board wishes to thank Mr. Maskerine for his contributions to the management of the Company since its inception. Mr. Maskerine will continue to act as Corporate Secretary and Treasurer. The Company is very pleased to have Mr. Yuen and Dr. Sun on its Board of Directors. Each brings valuable experience and expertise encompassing both the medical and legal fields and Asian markets.

Further to the news release dated November 10, 1999 the Company is pleased to announce that preparations for commercial production with its high yield EPO cell line are proceeding on schedule. The Company will host a visit to its Nanjing production plant for a number of fund managers, analysts, and newsletter writers at the end of November.

2410 total views, 0 today

Progress Report on Commercial Production

News

Dragon Pharmaceutical Inc.  is pleased to announce that Nanjing Huaxin (“Huaxin”) has purchased new bioreactors and that the preparations for commercial production with its high yield EPO cell line are proceeding well. Huaxin is currently working toward increasing the annual EPO production capacity up to a level of 5 million doses while significantly reducing the direct production cost.

The Chinese Medical Association (¡§CMA¡¨), at its September meeting, decided in principle to endorse Huaxin’s EPO as one of the “Recommended Medicines of the CMA”. After final endorsement, Huaxin will be permitted to print the name of the CMA on all packaging and prescription booklets. CMA only endorses the highest quality pharmaceutical products in China. The sales and acceptance of Huaxin¡¦s EPO will be positively affected by the endorsement.

The Company is also pleased to announce that Huaxin’s marketing network has been expanded considerably. Mr. Minghu Luo, the former head of marketing at the largest biotech company in China and a subsidiary of San Francisco based Hambrecht and Quist Investment Corp., was appointed as Huaxin’s Vice President Marketing. The expanded marketing network now covers all major metropolitan areas of China and Huaxin is now the largest EPO provider for several key cities such as Beijing. Sales of Huaxin’s EPO have increased significantly since the implementation of the new marketing network.

In addition, Huaxin has appointed a Marketing Manager and an Associate Marketing Manager. Both held previous appointments as marketing executives at the Chinese subsidiaries of several pharmaceutical companies including Bristol-Meyers Squibb, Merck, and SmithKline Beecham.

Dragon Pharmaceuticals is a biopharmaceutical company with the vision to become a leading biotechnology company in China through research, development, production, and marketing of bio-drugs. To further its goal, the Company acquired a 75% interest in Nanjing Huaxin Biotech Ltd. in Nanjing, China.

The foregoing includes forward looking statements and readers should not place undue reliance on such forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances.

2050 total views, 0 today

Dragon Closes Acquisition of Nanjing Huaxin Biotech Ltd

News

Dragon Pharmaceutical Inc. is pleased to announce that it has completed the acquisition of Nanjing Huaxin Biotech Ltd. (“Huaxin”) in Nanjing City, China as referred to in the previous news release dated July 7, 1999. The closing of this major transaction was marked by the issuance of a new business license by the Chinese government.

The acquisition makes Dragon Pharmaceuticals the largest producer of Erythropoietin (“EPO”) in China. The Company is now proceeding to increase production and sales of EPO by improving the technology at Huaxin. The Company has also formed a strategic alliance and partnership with Nanjing Medical (Group) Ltd., one of the largest pharmaceutical enterprises in China with extensive experience and expertise in the marketing and distribution of pharmaceutical products in China.

2270 total views, 1 today

Dragon Received Independent Confirmation of High Yield Erythropoietin (“EPO”) Cell Line

News

Dragon Pharmaceutical Inc. is pleased to announce that it has received the yield results of an independent test of the EPO cell line constructed by the Company’s Chinese subsidiary using CHO (Chinese Hamster Ovary) cells. The EPO cell line was tested at the Beijing Institute of Microbiology and Epidemiology, an independent lab.

The yield of the EPO cell line was 37 mg/L, calculated by measuring the EPO levels in the harvested media using ELISA. The management of the Company is very encouraged by such a high yield cell line and is confident that the Company’s Chinese subsidiary can produce EPO at much higher yields and at much lower costs than other Chinese EPO producers.

Dragon Pharmaceuticals is the largest producer of EPO in China and plans to apply its vector technology to other biodrug production. The Company has formed a strategic alliance and partnership with Nanjing Medical (Group) Ltd., one of the largest pharmaceutical enterprises in China with extensive experience and expertise in the marketing and distribution of pharmaceutical products in China.

1888 total views, 0 today

Acquisition of the Largest Erythropoietin (“EPO”) Producer in China

News

Dragon Pharmaceutical Inc. is pleased to announce that its subsidiary, Sanhe Kailong Biopharmaceutical Co., Ltd. (“Kailong”), has entered into an agreement to acquire a 75% interest in Nanjing Huaxin Biopharmaceutical Ltd. (“Huaxin”) of China. This strategic agreement provides Dragon with both the drug license and production permit for the manufacture and marketing of EPO in China.

Kailong will contribute a new vector technology to Huaxin that will allow Huaxin to produce EPO at lower costs and with significantly increased production. Huaxin was the first company to receive an EPO drug license from the Ministry of Health and the first to realize commercial production of the drug in China. It now produces approximately 500,000 doses of EPO, making it the largest domestic producer.

Huaxin has a group of high-tech professional employees, advanced equipment and facilities for biotech research, production and testing, and sales offices in 16 major cities in China. As part of the joint venture agreement, the Company has formed a strategic alliance and partnership with Nanjing Medical (Group) Ltd. (“NMC”). NMC is a Shanghai Stock Exchange-listed company and is one of the largest pharmaceutical enterprises in China. NMC brings extensive experience and expertise in the marketing and distribution of pharmaceutical products in China to the partnership.

The forgoing includes forward looking statements and readers should not place undue reliance on such forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances.

2715 total views, 0 today

Dragon Pharmaceuticals Announces Completion of Private Placement

News

Dragon Pharmaceuticals Inc. is pleased to announce the completion of the private placement of 2,000,000 common shares at US$0.50 per share. The proceeds will be used to fund the on-going development of the Company’s biotech projects in China.

The working capital of the Company currently stands at approximately US$1.4 million. The Company has invested approximately US$550,000 to date on drug licenses and other assets in China.

At a Board of Directors Meeting held on December 16, 1998, the Board appointed Dr. Longbin Liu as President and Mr. Shaun Maskerine as Secretary of the Company.

Dragon Pharmaceuticals Inc. is a biopharmaceutical company with the vision to become a leading biotechnology company in China through research, development, production, and marketing of previously commercialized bio-drugs.

2061 total views, 0 today

Page 8 of 8 1 6 7 8